blonanserin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
serotonin receptor antagonists (mostly 5-HT2) 388 132810-10-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • blonanserin
  • lonasen
  • AD-5423
  • Molecular weight: 367.51
  • Formula: C23H30FN3
  • CLOGP: 6.73
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 0
  • TPSA: 19.37
  • ALOGS: -4.01
  • ROTB: 3

Drug dosage:

None

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.93 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 4.875 Moderate 0.75
caco2-efflux Caco-2 efflux ratio (BA/AB) 2.710 Moderate 0.75
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 2.056 10^-6 cm/s Moderate 0.75
dh-clint Dog hepatocyte intrinsic clearance 11.220 uL/min/10^6 cells Moderate 0.75
dppb Dog plasma protein binding (% unbound) 0.160 % Moderate 0.75
fcs-ppb Fetal calf serum protein binding (% unbound) 0.690 % Moderate 0.75
herg hERG pIC50 5.610 pIC50 Moderate 0.75
hh-clint Human hepatocyte intrinsic clearance 3.631 uL/min/10^6 cells Moderate 0.75
hlm-clint Human liver microsomal intrinsic clearance 12.882 uL/min/mg protein Moderate 0.75
hppb Human plasma protein binding (% unbound) 0.320 % Moderate 0.75
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MET,NTRK2,PDK2,PDK4,PRKDC 15
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.106 Moderate 0.75
mh-clint Mouse hepatocyte intrinsic clearance 42.954 Moderate 0.75
mppb Mouse plasma protein binding (% unbound) 0.190 Moderate 0.75
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.447 Moderate 0.75
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 0.530 % Moderate 0.75
rh-clint Rat hepatocyte intrinsic clearance 41.210 uL/min/10^6 cells Moderate 0.75
rh-fuinc Rat hepatocyte fraction unbound in incubation 0.650 % Moderate 0.75
rppb Rat plasma protein binding (% unbound) 0.390 % Moderate 0.75
solubility-dd Solubility at pH 7.4 in DMSO 1.570 uM Moderate 0.75

Approvals:

DateAgencyCompanyOrphan
Jan. 25, 2008 PMDA Dainippon Sumitomo Pharma Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psychiatric symptom 82.88 49.22 17 601 7101 90620728
Hallucination, auditory 64.15 49.22 16 602 15959 90611870
Salivary hypersecretion 51.37 49.22 12 606 9080 90618749
Parkinsonism 51.05 49.22 13 605 14052 90613777

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pneumonia aspiration 50.13 38.60 18 347 50060 42570910
Procedural failure 49.23 38.60 6 359 65 42620905
Floppy iris syndrome 47.90 38.60 7 358 317 42620653

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psychiatric symptom 99.32 41.66 22 1057 9191 110579029
Hallucination, auditory 89.93 41.66 25 1054 26372 110561848
Pneumonia aspiration 65.84 41.66 26 1053 81207 110507013
Salivary hypersecretion 57.00 41.66 16 1063 17405 110570815
Delusion 47.88 41.66 15 1064 23740 110564480
Floppy iris syndrome 46.33 41.66 7 1072 347 110587873
Schizophrenia 44.90 41.66 14 1065 21812 110566408
Parkinsonism 44.68 41.66 14 1065 22173 110566047
Procedural failure 43.51 41.66 6 1073 155 110588065

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
CHEBI has role CHEBI:35476 antipsychotic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Schizophrenia indication 58214004 DOID:5419




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.05 Basic
pKa2 5.85 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 9.85 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 9.09 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.54 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 7.25 WOMBAT-PK

External reference:

IDSource
D01176 KEGG_DRUG
C0287983 UMLSCUI
CHEBI:31296 CHEBI
CHEMBL178803 ChEMBL_ID
DB09223 DRUGBANK_ID
C079310 MESH_SUPPLEMENTAL_RECORD_UI
125564 PUBCHEM_CID
7670 IUPHAR_LIGAND_ID
7563 INN_ID
AQ316B4F8C UNII
AQ316B4F8C INXIGHT DRUGS

Pharmaceutical products:

None